Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Group 1: Company Performance - Amgen's stock closed at $317.17, reflecting a +1.1% increase from the previous day, outperforming the S&P 500's daily gain of 0.64% [1] - Over the past month, Amgen's shares have risen by 7.74%, contrasting with the Medical sector's loss of 0.88% and the S&P 500's loss of 7.69% [1] Group 2: Upcoming Earnings - Amgen is expected to report an EPS of $4.18, representing a 5.56% increase compared to the same quarter last year [2] - The consensus estimate for revenue is $8.01 billion, indicating a 7.52% increase year-over-year [2] Group 3: Full-Year Estimates - Zacks Consensus Estimates project Amgen's earnings at $20.63 per share and revenue at $35 billion, reflecting year-over-year changes of +3.98% and +4.72%, respectively [3] - Recent adjustments to analyst estimates suggest a favorable outlook on Amgen's business health and profitability [3] Group 4: Valuation Metrics - Amgen's Forward P/E ratio is 15.2, which is lower than the industry's average Forward P/E of 19.99, indicating a valuation discount [6] - The company has a PEG ratio of 2.62, compared to the industry average PEG ratio of 1.55 [7] Group 5: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 73, placing it in the top 30% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]